+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bipolar Depression - Pipeline Insight, 2020

  • ID: 5148304
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 90 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2020

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Celon Pharma
  • Forest Laboratories
  • H. Lundbeck A/S
  • Iltoo
  • NeuroRx, Inc.
  • MORE
This “Bipolar Depression - Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Bipolar Depression Understanding

Bipolar Depression: Overview

Bipolar disorder, formerly called manic depression, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).

Symptoms

During the manic phase, symptoms can include:
  • High level of energy and activity
  • Irritable mood
  • Decreased need for sleep
  • Exaggerated, puffed-up self-esteem ("grandiosity")
  • Rapid or "pressured" speech
  • Rapid thoughts
  • Tendency to be easily distracted
  • Increased recklessness
  • False beliefs (delusions) or false perceptions (hallucinations)
Diagnosis

Since there are no medical tests to establish this diagnosis, a mental health professional diagnoses bipolar disorder based on a person's history and symptoms. The diagnosis is based not just on the current symptoms, but also take into account the problems and symptoms that have occurred through a person's life.

Treatment

A combination of medication and talk therapy is most helpful. Often more than one medication is needed to keep the symptoms in check.

Mood Stabilizers: The best-known and oldest mood stabilizer is lithium carbonate, which can reduce the symptoms of mania and prevent them from returning.

Antipsychotic Medications: In recent years, studies have shown that some of the newer antipsychotic medications can be effective for controlling bipolar disorder symptoms. Side effects often have to be balanced against the helpful effects of these drugs:
  • Olanzapine: sleepiness, dry mouth, dizziness and weight gain.
  • Risperidone: sleepiness, restlessness and nausea.
  • Quetiapine: dry mouth, sleepiness, weight gain and dizziness.
  • Ziprasidone: sleepiness, dizziness, restlessness, nausea and tremor.
  • Aripiprazole: nausea, stomach upset, sleepiness (or sleeplessness) or restlessness.
  • Asenapine: sleepiness, restlessness, tremor, stiffness, dizziness, mouth or tongue numbness.
Bipolar Depression Emerging Drugs Chapters

This segment of the Bipolar Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bipolar Depression Emerging Drugs

Lumateperone: Intra-Cellular Therapies

Lumateperone is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia, and currently in development for bipolar depression and other neurological indications. The most common side effects include sleepiness and dry mouth.

Zuranolone: SAGE Therapeutics

Zuranolone is an investigational medication which is under development by SAGE Therapeutics for the treatment of depressive disorders and a variety of other indications. It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABAA receptor.

Bipolar Depression: Therapeutic Assessment

This segment of the report provides insights about the different Bipolar Depression drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bipolar Depression

There are approx. 20+ key companies which are developing the therapies for Bipolar Depression. The companies which have their Bipolar Depression drug candidates in the most advanced stage, i.e. phase III include, SAGE Therapeutics.

Phases

This report covers around 20+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bipolar Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Depression drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve Bipolar Depression.
  • In July 2019, Intra-Cellular Therapies announced top-line results from two Phase 3 clinical trials (Study 401 and Study 404) evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p< 0.001; effect size = 0.56). Study 404 also met its key secondary endpoint, Clinical Global Impression Scale for Bipolar for Severity of Illness (CGI-BP-S) Total Score (p< 0.001; effect size = 0.46). In both trials, lumateperone demonstrated a favorable safety profile and was generally well-tolerated.
Bipolar Depression Report Insights
  • Bipolar Depression Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Bipolar Depression Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Bipolar Depression drugs?
  • How many Bipolar Depression drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bipolar Depression?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bipolar Depression therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bipolar Depression and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Sunovion
  • Sumitomo Pharmaceutical
  • H. Lundbeck A/S
  • NeuroRx, Inc.
  • Korea Otsuka Pharmaceutical Co., Ltd.
  • Intra-Cellular Therapies, Inc.
  • Janssen Research & Development
  • Forest Laboratories
  • Celon Pharma
  • Astellas Pharma Inc
  • Iltoo Pharma
Key Products
  • Lurasidone
  • Vortioxetine
  • Lumateperone
  • JNJ-18038683
  • Cariprazine
  • Esketamine
  • FK949E
  • ILT101
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Celon Pharma
  • Forest Laboratories
  • H. Lundbeck A/S
  • Iltoo
  • NeuroRx, Inc.
  • MORE
Introduction

Executive Summary

Bipolar Depression: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Bipolar Depression - Analytical Perspective

In-depth Commercial Assessment
  • Bipolar Depression companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bipolar Depression Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
NRX100: NeuroRx
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
SEP 4199: Sunovion Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Zuranolone: SAGE Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
SKL PSY: SK biopharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
Drug Name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Bipolar Depression Key Companies

Bipolar Depression Key Products

Bipolar Depression- Unmet Needs

Bipolar Depression- Market Drivers and Barriers

Bipolar Depression- Future Perspectives and Conclusion

Bipolar Depression Analyst Views

Bipolar Depression Key Companies

Appendix

List of Tables
Table 1 Total Products for Bipolar Depression
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Bipolar Depression
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Sunovion
  • Sumitomo Pharmaceutical
  • H. Lundbeck A/S
  • NeuroRx, Inc.
  • Korea Otsuka Pharmaceutical Co., Ltd.
  • Intra-Cellular Therapies, Inc.
  • Janssen Research & Development
  • Forest Laboratories
  • Celon Pharma
  • Astellas Pharma Inc
  • Iltoo
Note: Product cover images may vary from those shown
Adroll
adroll